Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease
Gain Therapeutics宣布启动GT-02287的Phase 1临床试验的Multiple Ascending Dose (MAD)部分 - GT-02287已被证明可以恢复溶酶体酶葡萄糖酸酶(GCase)的功能，有望减缓帕金森病的进展[3] - GT-02287是一种口服、穿透血脑屏障的小分子药物，可以恢复蛋白酶酶的功能，改善运动功能[4]